Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
AdAlta Ltd. ( (AU:1AD) ) has shared an announcement.
AdAlta Limited (ASX:1AD) announced its participation in the Biotech Showcase 2025 during JPMorgan Healthcare Week, highlighting its ‘East to West’ cellular immunotherapy strategy and its lead asset, AD-214. This involvement underscores AdAlta’s progress in advancing its innovative therapeutic solutions for fibrotic diseases and cancer, potentially attracting partnerships and investments, which could bolster its position in the biotech industry and offer significant implications for stakeholders.
More about AdAlta Ltd.
AdAlta Limited is a clinical stage drug development company based in Melbourne, Australia, specializing in the creation of protein and cell therapeutics using its proprietary i-body technology. This technology, inspired by shark antibodies and developed into human proteins, targets challenging drug problems, particularly focusing on fibrotic diseases and cancer. AdAlta’s lead product, AD-214, is designed to treat idiopathic pulmonary fibrosis and other fibrotic diseases, marking a novel approach in this medical field.
YTD Price Performance: -20.0%
Average Trading Volume: 422,422
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.1M
See more data about 1AD stock on TipRanks’ Stock Analysis page.
